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Abstract
Background: Sudden cardiac death (SCD) mostly resulting from ventricular arrhythmia remains  
a cause of mortality in 19–30% of adults with congenital heart defects. Indications for im-
plantable cardioverter-defibrillators in primary prophylaxis are still under research. Microvolt 
T wave alternans (MTWA) is one of the SCD risk stratification methods. We determined the 
incidence of MTWA in these patients and its coincidence with ventricular arrhythmia, as well 
as risk factors of ventricular arrhythmia/SCD.
Methods: 204 patients with complex congenital heart anomalies and 45 healthy volunteers 
underwent ambulatory ECG monitoring, a cardiopulmonary test, B-type natriuretic peptide 
assessment, echocardiography and an MTWA test. After excluding technically inadequate 
traces, the remaining 179 patients and 43 controls were classified into MTWA positive (+), 
negative (–) and indeterminate (ind) subgroups. Additionally, MTWA (+) and MTWA (ind) 
formed an ‘abnormal’ group, labeled MTWA (non–).
Results: Abnormal MTWA was observed more frequently in the study group compared to 
controls (59 [33.0%] vs. 1 [2.3%], p = 0.000001). The MTWA (non–) group compared to 
MTWA (–) presented a higher number of males (61.0% vs. 37.5%, p = 0.005), predominance 
of patients with NYHA > I (44.1% vs. 25.0%, p = 0.007), pulmonary hypertension (16.9% vs. 
0.8%, p = 0.00007), lower blood saturation (97% [73–100] vs. 99% [69–100], p = 0.0003), 
higher incidence of malignant arrhythmia (9 [15.2%] vs. 3 [2.5%], p = 0.003), lower peak 
oxygen consumption VO2 [mL/kg/min] (23.1 ± 5.9 vs. 26.3 ± 6.7, p = 0.002), higher VE/ 
/VCO2slope (36.0 [25–74] vs. 31.0 [21–58], p = 0.01). Multivariate logistic regression analy-
sis proved that pulmonary hypertension (OR = 13.7, p = 0.03), male gender (OR = 10.4,  
p = 0.00002), VE/VCO2slope (OR = 1.07, p = 0.045) and VO2 (OR = 0.89, p = 0.04) in-
crease the probability of MTWA (non–).
Conclusions: Abnormal MTWA is more frequent in adults with congenital heart diseases 
than in the healthy population. Its probability increases in patients demonstrating clinical find-
ings conducive to lethal arrhythmia like heart failure and pulmonary hypertension. (Cardiol J 
2014; 21, 2: 144–151)
Key words: congenital heart disease, T-wave alternans, sudden cardiac death, 
ventricular arrhythmia, systemic right ventricle, univentricular heart,  
tetralogy of Fallot
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Introduction
Sudden cardiac death (SCD), mostly resulting 
from ventricular arrhythmia, remains a cause of 
mortality in 19–30% of adults with congenital 
heart defects [1–5]. Such dramatic events in this 
relatively young population prompt to investigate 
indications for implantable cardioverter-defibril-
lator (ICD) therapy in primary prophylaxis. The 
mechanisms leading to ventricular arrhythmia in 
these patients are still under research. However, 
ventricular arrhythmia is considered to result from 
myocardial fibrosis caused by cyanosis and/or in-
adequate intraoperative cardioprotection, as well 
as scars after ventriculotomy. Moreover, hemody-
namic changes leading to dilation of ventricles (or 
single ventricle) and a consequently increased wall 
stress resulting in areas of electrical inhomogeneity 
within myocardium also contribute to these rhythm 
disturbances [3–8]. All mentioned pathological 
phenomena may additionally lead to heart failure 
which is a known cause of malignant arrhythmia 
and SCD per se [5, 6, 8, 9]. The decision on ICD 
therapy is often based on electrophysiology study 
which has demonstrated better prognostic value 
when conducted in preselected group of patients 
[6, 10]. Such preselection of subjects potentially 
endangered with SCD is performed with the use of 
some noninvasive methods, including a microvolt 
T wave alternans (MTWA) — an electrocardiographic 
(ECG) phenomenon displaying inhomogeneity of the 
myocardial repolarization process. It was proved that 
the inhomogeneity of the intracardiac repolarization 
leads to a dispersion of the depolarizing wave, re-
-entry phenomenon and, as a consequence, initiation 
of the ventricular arrhythmia [9, 11, 12]. A progno-
stic value of MTWA was strongly suggested among 
patients with ischemic and nonischemic advanced 
heart failure [13–16]. To our knowledge, the issue 
of spectral MTWA has been addressed in merely 
2 papers regarding pediatric population and only 
1 concerning adults with congenital heart diseases 
(CHD) characterized by right ventricle pathology or 
single ventricle physiology that was conducted by 
our team [17–19]. Therefore, a necessity to continue 
this research among grown-up patients with other 
congenital cardiac anomalies seems undeniable.
The aim of the study was to evaluate the 
incidence of spectral MTWA in adults with CHD; 
to determine its coincidence with malignant 
and potentially malignant arrhythmia, as well 
as other clinical and demographical findings 
conducive to malignant arrhythmia and SCD in 
the study group.
Methods
The study protocol, as approved by the Ethics 
Committee of the University of Medical Sciences 
in Poznan, conformed to the ethical guidelines of 
the 1975 Declaration of Helsinki. Informed consent 
was obtained from all subjects.
The study group was selected from the popu-
lation followed-up in 2010–2012 at the Congenital 
Heart Disease Outpatient Clinic of the 1st Depart-
ment of Cardiology, University of Medical Sciences 
in Poznan, Poland. Out of 204 consecutive adults 
with complex CHD and 45 healthy volunteers, 
after exclusion of MTWA tests impossible to 
interpret due to technical artifacts, 179 patients 
and 43 controls were further analyzed. The pa-
tients (81 males), aged 18–75 (median 30) years, 
with 126 (70.4%) being operated at the age of 
0.5–21 (median 5) years (Table 1) demonstrated 
the following defects: 5 (5.8%) — common arterial 
trunk, 9 (5.0%) — corrected transposition of great 
arteries, 4 (2.2%) — double outlet right ventricle, 
27 (15.1%) — Ebstein anomaly, 8 (4.5%) — Eisen-
menger syndrome, 18 (10.0%) — transposition 
of the great arteries, 105 (50.3%) tetralogy of 
Table 1. Demographic and clinical characteristic of the study and control groups.
Study group 
(n = 179)
Control group  
(n = 43)
P (study vs.  
control group)
Males 81 (45.3%) 22 (51.1%) 0.5
Age [years]; median (min–max) 30 (18–75) 28 (18–65) 0.52
Body mass index [kg/m2]; median (min–max) 21.8 (15.6–38.0) 23.0 (17.3–32.0) 0.323
New York Heart Association > I 56 (31.3%) 0 (0.0%) < 0.00001
Blood oxygen saturation [%]; median (min–max) 98 (69–100) 100 (99–100) 0.0001
Operated 126 (70.4%) – –
Age at operation [years]; median (min–max) 5.0 (0.5–21) – –
Pulmonary hypertension 11 (6.1%) – –
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Fallot, 18 (10.0%) — univentricular heart including: 
8 — tricuspid atresia, 3 — corrected transposition, 
4 — double inlet left ventricle, 3 — common atrio-
ventricular canal. The control group consisted of 
43 healthy volunteers (22 males) aged 18–65 (me-
dian 28) years. The main inclusion criterion was 
sinus rhythm. Exclusion criteria were: persistent 
atrial fibrillation, permanent ventricular pacing, 
serum creatinine level > 140 μmol/L, serum aspar-
tate transaminase level exceeding twice the upper 
limit of normal, pulmonary diseases.
Functional status was evaluated according to 
New York Heart Association (NYHA) classifica-
tion. Blood oxygen saturation was assessed using 
pulse oximetry.
Microvolt T wave alternans was analyzed in 
204 patients during treadmill test while receiv-
ing their usual medications, including b-blocker 
therapy [12]. High-resolution electrodes (Micro-V 
Alternans Sensors, Cambridge Heart Inc.) were 
applied using Frank orthogonal configuration. 
MTWA was recorded during a heart rate (HR)- 
-based exercise protocol using CH2000 (Cambridge 
Heart Inc., Bedford, MA, USA) using spectral 
method [11]. The test was considered positive 
if the significant MTWA (i.e. alternans voltage 
≥ 1.8 μV and alternans ratio > 3.0) appeared at an 
onset HR £ 110 bpm, was present for ≥ 1 min in 
any orthogonal lead or 2 adjacent precordial leads 
and sustained as long as HR remained above the 
patient specific onset HR. The test was classified 
as negative if sustained MTWA was absent at HR 
£ 110 bpm and if there was ≥ 1 min at HR ≥ 105 bpm 
of artifact-free trace (noise level < 1.8 μV, ectopy 
< 10%). Otherwise, the test was considered in-
determinate and immediately repeated in order to 
reduce the number of such results. As generally ac-
cepted [12], the indeterminate test may be caused 
either by patient factors (including: 1) excessive 
ectopy during exercise, 2) unsustained MTWA, 
3) failure to achieve HR = 105 bpm) or technical 
factors (including: 1) a noisy recording, 2) failure to 
maintain HR between 105 and 110 bpm for ≥ 1 min). 
The indeterminate results due to technical factors 
obtained in 25 patients were ultimately excluded 
from further analysis, as a consequence the analysis 
was performed in 179 subjects. Considering the 
similar prognostic significance, all tests classified 
as positive or indeterminate due to patient factors 
were combined into a common group labeled ‘non-
negative’ [MTWA (non–)], i.e. abnormal. The analysis 
of MTWA results and statistical calculations were 
performed by the researchers blinded to all ECG, 
clinical and laboratory findings.
Echocardiography was performed with VIVID 
7 GE Medical System device, using 1.5–2.5 Hz 
probe in 2-dimensional, M- and Doppler modes. 
The diagnoses of anatomical anomalies were set 
according to the current recommendations of the 
European Society of Cardiology (ESC) [7]. As in 
other studies [20], the diagnosis of pulmonary arte-
rial hypertension  was based on echocardiography. 
The estimation of pulmonary arterial pressure 
(PAP) was based on the peak velocity of the jet of 
tricuspid regurgitation enabling to calculate right 
ventricular systolic pressure (using Bernoulli 
equation). After excluding pulmonary stenosis, 
PAP was calculated as the sum of right ventricular 
systolic pressure and right atrial pressure (esti-
mated as 5–15 mm Hg depending on the diameter 
and respiratory variation of the inferior vena cava). 
According to the current guidelines we considered 
the criterion of estimated PAP ≥ 37 mm Hg com-
bined with additional echocardiographic variables 
suggestive of pulmonary arterial hypertension 
a sufficient basis to set this diagnosis [20].
The cardiopulmonary exercise treadmill test 
was performed according to the modified Bruce 
protocol (adding stage 0–3 min, 1.7 km/h, 5% 
grading) and was symptom limited. The equipment 
was calibrated with a standard gas mixture before 
each test. Patients were encouraged to continue 
the exercise until the respiratory exchange ratio 
(RER) exceeded 1. Oxygen uptake (peakVO2), 
carbon dioxide production (VCO2) and minute 
ventilation were measured with breath by breath 
technique using Sensor Medics, model Vmax29. 
PeakVO2 was defined as the average for the last 
20 s of exercise and expressed as [mL/kg/min] and 
[mL/min], as well as the percentage ranges predicted 
for sex, age, height and weight [21]. A ventilation/ 
/carbon dioxide slope (VE/VCO2slope) was asses-
sed by linear regression for the whole exercise. 
A standard 12-lead ECG was continuously recor-
ded. Due to physical disability a cardiopulmonary 
test was not performed in 3 patients.
Ambulatory 24-hour ECG monitoring was re-
gistered on the same day as the other tests using 
CardioScan12.0 Premier, Oxford system. Additio-
nally, all previous results of ambulatory ECG avai-
lable in the patients’ medical records were analyzed 
for presence of ventricular arrhythmia, which was 
classified as: excessive ventricular ectopy (ventri-
cular premature beats — VPB ≥ 10/h), episodes 
of non-sustained ventricular tachycardia — nsVT 
(presence of ≥ 3 consecutive ventricular beats at 
a rate greater than 100 bpm, terminating sponta-
neously in less than 30 s), episodes of sustained 
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ventricular tachycardia — VT (ventricular tachy-
cardia greater than 30 s in duration or hemodyna-
mically unstable) [6]. According to the classification 
regarding patients with structural heart disease 
[6] this findings were divided into two groups: 
potentially malignant ventricular arrhythmia (VPB 
> 10/h and/or nsVT) and malignant ventricular 
arrhythmia (VT). For the purposes of analysis, 
a group comprising of patients with any of the spe-
cified forms of ventricular arrhythmia was formed 
and labeled ‘VT/nsVT/VPB > 10/h’.
QRS duration was adopted as the longest 
value measured among all 12 leads in standard 
ECG.
Serum B-type natriuretic peptide (BNP) level 
was measured in the venous blood samples taken 
after 15 min of rest in supine position using the 
Abbott AxSYM Immunoassay system.
Statistical analysis
Continuous variables were summarized by 
mean ± SD or median and minimal–maximal 
values, depending on normality of distribution as-
sessed with Shapiro-Wilk test. Variables following 
normal distribution were analyzed using Student’s 
t test or Welch test, otherwise non-parametrical 
U Mann-Whitney test comparing the two groups 
was performed. Categorical variables are repre-
sented by frequencies and percentages and calcu-
lated as c2 test with Yates’s correction or Fisher’s 
exact test. Factors associated with non-negative 
MTWA were assessed by linear logistic regression. 
P < 0.05 were considered statistically significant.
Results
The incidence of MTWA (+), MTWA (ind), as 
well as MTWA (non–) in the study group was signi-
ficantly higher than among the controls (Table 2).
Comparison between the subgroups with 
different MTWA results demonstrated male pre-
dominance among MTWA (+) and MTWA (non–) 
patients in contrast to MTWA (–) group. Subjects 
with MTWA (non–) manifested heart failure symp-
toms — NYHA > I significantly more often when 
compared to MTWA (–) subgroup. Blood saturation 
was higher in MTWA (–) patients than in subgroups 
with MTWA (+) and MTWA (non–). Pulmonary 
hypertension was also less common in MTWA (–) 
group when compared to MTWA (+) and MTWA 
(non–) (Table 3).
As shown in Table 4 the incidence of malig-
nant (VT) and potentially malignant (nsVT/VPB 
> 10/h) arrhythmia as well as any specified form 
of ventricular arrhythmia (VT/nsVT/VPB > 10/h) 
was significantly higher in subjects with MTWA 
(non–) as compared to MTWA (–).
The cardiopulmonary test revealed significan-
tly lower values of peak oxygen consumption (VO2, 
[mL/kg/min]) in MTWA (+) and MTWA (non–) 
subgroups than in MTWA (–) patients. Similar 
differences were observed in percentage values 
of maximal predicted oxygen consumption (%VO2, 
[mL/kg/min]), as well as %VO2 [L/min]. Patients 
demonstrated a higher ventilation/carbon dioxide 
index — VE/VCO2slope and higher serum BNP 
concentration compared to those with MTWA (–) 
(Table 5).
As shown in univariate linear logistic regres-
sion analysis, the factors increasing probability of 
abnormal MTWA were: pulmonary hypertension, 
sustained ventricular arrhythmia, as well as any 
specified form of ventricular arrhythmia, male 
gender, NYHA > I, increased VE/VCO2slope, ab-
normal SO2 as well as decreased values of %VO2 
[mL/kg/min], %VO2 [L/min] and VO2 [mL/kg/min]. 
A multivariate logistic regression analysis proved 
a significant predictive role of: pulmonary hyper-
tension, male gender, VE/VCO2slope and VO2 [mL/ 
/kg/min] (Table 6).
Discussion
A positive MTWA test was obtained in 17.3% 
of the analyzed patients, whereas an indetermina-
te result was obtained in 15.6% of them. Both of 
Table 2. Microvolt T-wave alternans (MTWA) in the study and control groups.
Study group (n = 179) Control group (n = 43) P (study vs. control group)
MTWA (+) 31 (17.3%) 1 (2.3%) 0.008
MTWA (ind) 28 (15.6%) 0 (0.0%) 0.003
MTWA (non–) 59 (33.0%) 1 (2.3%) 0.000001
MTWA (–) 120 (67.0%) 42 (97.7%) 0.00001
MTWA (+) — positive result; MTWA (ind) — result indeterminate due to patient factors; MTWA (–) — negative result; MTWA (non–) — non-
-negative (abnormal) result
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these values are significantly higher than among 
healthy subjects with one positive test (2.3% of 
the group) and none indeterminate MTWA result 
[22]. The incidence of MTWA (+) observed by us 
was comparable to the values obtained in our pre-
vious study regarding adults with congenital defect 
characterized by the right ventricle pathology or 
univentricular heart, where the incidence of posi-
tive, as well as indeterminate MTWA accounted 
for 17.6% each. As far as pediatric CHD population 
is concerned, Alexander et al. [17] described this 
phenomenon in 14% of patients, whereas Cheung 
et al. [18] described it in 14.2% of children after 
tetralogy of Fallot repair.
There is, however, a great difference between 
the results obtained by our team and the trials 
conducted on patients with advanced ischemic/ 
/nonischemic heart failure, in which the incidence of 
MTWA (+) reached 37–52% [13–16]. Although not 
all researchers confirmed the prognostic value of 
the MTWA phenomenon, the analysis of numerous 
studies demonstrated its significant diagnostic role 
excluding the probability of SCD [10–12, 15]. On 
the other hand, positive and indeterminate MTWA 
results were proved to have similar prognostic 
value, therefore being qualified together as non-
-negative (abnormal) [10, 13–16]. The abnormal 
MTWA was seen in 32.9% of our patients, which 
Table 3. Differences in demographic or clinical features between the subgroups defined by microvolt 
T-wave alternans (MTWA) result.
Patients  
(n = 179)
MTWA (+) 
(n = 31)
MTWA (ind)  
(n = 28)
MTWA 
(non–)  
(n = 59)
MTWA  
(–)  
(n = 120)
P: MTWA 
(+) vs. 
MTWA (–)
P: MTWA 
(non–) vs. 
MTWA (–)
Males 81  
(45.3%)
24  
(77.4%)
12  
(42.9%)
36  
(61.0%)
45  
(37.5%)
0.0002 0.005
Age [years];  
median (min–max)
30  
(18–75)
29  
(20–65)
34  
(20–75)
31  
(20–75)
30  
(19–74)
0.982 0.325
Body mass index  
[kg/m2]; median 
(min–max)
21.8  
(15.6–38.0)
22.3  
(15.8–33.8)
21.2  
(15.6–38.1)
21.8  
(15.6–38.1)
21.8  
(15.7–37.2)
0.68 0.968
NYHA > I 56  
(31.3%)
10  
(32.3%)
16  
(57.1%)
26  
(44.1%)
30  
(25.0%)
0.339 0.007
Blood oxygen  
saturation [%];  
median (min–max)
98  
(69–100)
97  
(75–100)
97.5  
(73–100)
97  
(73–100)
99  
(69–100)
0.009 0.0003
Operated 126  
(70.4%)
23  
(74.2%)
15  
(53.6%)
38  
(64.4%)
88  
(73.3%)
1.0 0.291
Age at operation  
[years]; median 
(min–max)
5.0  
(0.5–21)
4  
(0.5–17)
7  
(0.5–21)
3  
(0.5–21)
3  
(0.5–16)
0.817 0.404
Pulmonary  
hypertension
11  
(6.1%)
3  
(9.7%)
7  
(25.0%)
10  
(16.9%)
1  
(0.8%)
0.03 0.00007
Table 4. Differences in ventricular arrhythmia incidence between the subgroups defined by microvolt 
T-wave alternans (MTWA) result.
Patients  
(n = 179)
MTWA 
(+)  
(n = 31)
MTWA 
(ind)  
(n = 28)
MTWA 
(non–)  
(n = 59)
MTWA  
(–)  
(n = 120)
P: MTWA 
(+) vs. 
MTWA (–)
P: MTWA 
(non–) vs. 
MTWA (–)
VT 12 (6.7%) 2 (6.9%) 7 (25.0%) 9 (15.2%) 3 (2.5%) 0.25 0.003
nsVT/VPB > 10/h 40 
(22.3%)
7  
(22.6%)
13 
(68.4%)
20 
(33.9%)
20 
(16.7%)
0.439 0.02
VT/nsVT/VPB > 10/h 44 
(24.6%)
8  
(25.8%)
15 
(53.6%)
23 
(39.0%)
21 
(17.5%)
0.312 0.003
MTWA (+) — positive result; MTWA (ind) — indeterminate result; MTWA (–) — negative result; MTWA (non–) — non-negative result;  
VPB ≥ 10/h — excessive ventricular ectopy; nsVT — non-sustained ventricular tachycardia; VT — sustained ventricular tachycardia
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was significantly less than the values presented 
in studies quoted above regarding ischemic and 
nonischemic heart failure (67–73% of patients). 
It is presumably the younger age of our patients, 
who were mostly in their forties, whereas subje-
cts enrolled in the mentioned trials reached their 
6th or 7th decade of life, that contributed to such 
a difference in MTWA incidence. Moreover, the 
functional status of our congenital heart diseases 
patients was also much better, with 85% being in 
NYHA class I.
Our study showed that a previous history of 
malignant and potentially malignant arrhythmia 
was significantly more frequent in patients with 
abnormal MTWA compared with the MTWA (–) 
group. However, the we did not confirm the re-
lationship of that arrhythmia reported in the past 
with abnormal MTWA, which is congruent with 
the outcome of the analysis conducted in pediatric 
CHD population [17].
Although the ESC and AHA experts [6, 9] 
recommend ambulatory ECG monitoring as 
Table 6. Factors increasing probability of abnormal microvolt T-wave alternans (MTWA) in uni- and 
multivariate logistic regression analysis.
Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Pulmonary hypertension [%] 24.29 (2.97–198.85) 0.003 13.62 (1.24–149.5) 0.03
VT [%] 7.31 (1.88–28.49) 0.004 8.4 (0.69–102.04) 0.095
VT/nsVT/VPB ≥ 10/h [%] 3.01 (1.48–6.12) 0.002 1.54 (0.04–55.1) 0.814
Males [%] 2.61 (1.37–4.97) 0.003 10.39 (3.55–30.42) 0.00002
NYHA > I [%] 2.06 (1.21–3.49) 0.007 1.27 (0.47–3.35) 0.636
VE/VCO2 slope 1.07 (1.02–1.11) 0.002 1.07 (1.00–1.14) 0.045
%VO2 [mL/kg/min] 0.97 (0.94–0.99) 0.007 1.01 (0.95–1.08) 0.711
%VO2 [L/min] 0.97 (0.94–0.99) 0.005 1.00 (0.95–1.06) 0.929
SO2 [%] 0.93 (0.88–0.98) 0.006 1.04 (0.94–1.15) 0.379
VO2 [mL/kg/min] 0.92 (0.87–0.97) 0.003 0.89 (0.80–0.99) 0.04
OR — odds ratio; CI — confidential interval; VT — sustained ventricular tachycardia; VPB ≥ 10/h — excessive ventricular ectopy; nsVT — non-
-sustained ventricular tachycardia; NYHA — New York Heart Association; VE/VCO2slope —ventilation/carbon dioxide slope; VO2 — peak  
oxygen uptake on exercise, SO2 — oxygen blood saturation
Table 5. Differences in the chosen cardiopulmonary parameters and serum B-type natriuretic peptide 
level between the subgroups defined by microvolt T-wave alternans (MTWA) result.
Patients  
(n = 174)
MTWA (+) 
(n = 30)
MTWA (ind) 
(n = 27)
MTWA 
(non–)  
(n = 57)
MTWA  
(–)  
(n = 117)
P: MTWA 
(+) vs. 
MTWA (–)
P: MTWA 
(non–) vs. 
MTWA (–)
BNP [pg/mL];  
median (min–max)
39.9  
(6.2–598.4)
35.8  
(9.2–195.4)
60.4  
(25.1–343.5)
50.8  
(9.2–343.5)
35.5  
(6.2–5984)
0.398 0.03
VO2 [mL/kg/min] 25.2 ± 6.6 23.8 ± 5.1 22.2 ± 6.6 23.1 ± 5.9 26.3 ± 6.7 0.03 0.002
%VO2 [mL/kg/min]; 
median (min–max)
64.0  
(28.0–118.0)
60.5  
(36.0–78.0)
63.0  
(28.0–86.0)
61.0  
(28.0–86.0)
64.5  
(30.0–118.0)
0.01 0.01
VO2 [L/min];  
median (min–max)
1.5  
(0.5–2.8)
1.6  
(0.5–2.6)
1.2  
(0.5–2.9)
1.5  
(0.5–2.9)
1.6  
(0.7–2.8)
0.883 0.088
%VO2 [L/min];  
median (min–max)
64.0  
(26.0–108.0)
57.5  
(33.0–78.0)
59.0  
(31.0–106.0)
59.0  
(31.0–106.0)
66.0  
(26.0–108.0)
0.003 0.002
VE/VCO2slope;  
median (min–max)
32.0  
(21–74)
33.5  
(25–74)
39.0  
(26–66)
36.0  
(25–74)
31.0  
(21–58)
0.247 0.01
RER;  
median (min–max)
1.02  
(0.95–1.19)
1.01  
(1.0–1.09)
1.01  
(1.0–1.13)
1.01  
(1.0–1.13)
1.02  
(0.95–1.19)
0.167 0.141
MTWA (+) — positive result; MTWA (ind) — result indeterminate due to patient factors; MTWA (–) — negative result; MTWA (non–) — non-
-negative result; BNP — B-type natriuretic peptide; VO2 — peak oxygen uptake on exercise; VE/VCO2slope — ventilation/carbon dioxide slope, 
RER — respiratory exchange ratio
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a method of SCD risk stratification in patients with 
structurally diseased hearts (which undeniably 
concerns our study group), the prognostic role of 
malignant arrhythmia episodes observed during 
this test has never been confirmed in the general 
population. It is known, however, that arrhythmia 
increases mortality among subjects with advanced 
heart failure simultaneously taking part in heart 
failure pathogenesis. On malignant arrhythmia risk 
stratification algorithm the analysis of ambulatory 
ECG monitoring is justifiable when combined with 
other clinical findings increasing this risk. A com-
prehensive analysis by Cutler and Rosenbaum [10], 
regarding the papers published in the last decade, 
undeniably demonstrated an algorithm considering 
a few carefully combined ventricular arrhythmia 
risk factors in patients with ischemic or nonis-
chemic cardiomyopathy to enable more accurate 
qualification for ICD in primary prevention of SCD, 
exceeding even outcomes of implantations made 
in secondary prophylaxis. It seems reasonable to 
apply these rules also in CHD population.
Therefore, we expanded the analysis to deter-
mine which demographical and clinical findings of 
possible prognostic value for SCD are observed in 
subjects with abnormal MTWA. The association 
between a patient’s age and MTWA result was not 
confirmed, although in the general population the risk 
of SCD increases significantly after the age of 35 [6]. 
In the analyzed subjects who have been affected with 
the disease since birth, it is rather the severity of 
a given defect that worsens a patient’s prognosis. Also 
the fact of undergoing potentially beneficial cardio-
-surgery turned out to have no prognostic value, as 
repairs are usually performed in advanced cardiac 
anomalies and remaining scars may be the origin 
of arrhythmia [1–5]. Our study showed in turn the 
predominance of males among MTWA (non–) patients 
with male gender being also a factor that increases 
the probability of this phenomenon. This confirms 
the observation that men die more often due to SCD 
than women [6]. In the CHD population male gender 
was proved to be a risk factor of life-threatening 
arrhythmia [23, 24], as well as of total mortality [2].
Our study demonstrated worse exercise tole-
rance in patients with abnormal MTWA when com-
pared to the MTWA (–) group and their functional 
status was more often impaired (NYHA > I). It is 
proved that deterioration in NYHA classification 
has an adverse prognostic value for SCD in pa-
tients with congenital heart anomaly [7, 25, 26]. 
This association might be due to the heart failure-
-related hypercatecholaminemia that increases 
the risk of ventricular arrhythmia, simultaneously 
confirming the rationale for including MTWA into 
SCD risk stratification in the analyzed population 
[27]. However, our study neither proved higher 
NYHA class nor higher serum BNP concentration 
to increase the probability of abnormal MTWA. We 
confirmed the prognostic value of cardiopulmonary 
parameters: ventilation-carbon dioxide production 
relationship (VE/VCO2slope) and peak oxygen 
consumption (VO2 [mL/kg/min]). A predictive role 
of the latter parameter for ventricular arrhyth-
mia in CHD population was also proved by other 
authors [23].
Other factors contributing to heart failure 
pathogenesis in patients with that heart anoma-
ly are elevated pulmonary and decreased blood 
saturation, often coexisting, hence difficult to be 
analyzed separately [26, 27]. We observed these 
2 clinical features more often in patients with abnor-
mal MTWA, though only pulmonary hypertension 
was confirmed to increase the probability of this 
phenomenon. Sub-pulmonary ventricle pressure 
overload along with cyanosis-related tissue hypo-
xia, as well as segmental dilation and tortuosity of 
the coronary arteries typical for increased blood 
viscosity lead to the myocardial fibrosis creating 
a substrate for ventricular arrhythmia [28, 29].
Similarly to the general cardiologic population 
[13–16], among patients with CHD the abnormal 
MTWA was observed more frequent in those with 
advanced heart failure, already proved to be linked 
to ventricular arrhythmia. The parameters deter-
mining the cardiac impairment in this anatomically 
diversified population turned out to be the factors 
increasing probability of non-negative MTWA. 
Although the unquestionable relationship between 
this phenomenon and malignant or potentially 
malignant arrhythmia was not stated, the obtai-
ned results give the rationale for applying MTWA 
test in SCD risk stratification algorithm for CHD 
patients. Further studies are required to confirm 
the value of this diagnostic tool.
Limitations of the study
The main methodological limitations of our 
study are the lack of prospective analysis and the 
limited number of patients. A smaller group size 
than in ischemic and nonischemic heart failure 
trials is characteristic for this unique population 
and is seen in the majority of CHD studies. The 
number of patients, as well as the incidence of po-
tential end points determine the follow-up period, 
which, according to the statistical rules, should last 
more than 10 years and has been already started 
by our team [8, 30].
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Conclusions
The incidence of abnormal MTWA among pa-
tients with congenital heart defects is higher than 
in healthy subjects. The probability of this pheno-
menon increases in patients with clinical findings 
possibly conducive to lethal arrhythmia including 
heart failure and pulmonary hypertension, as well 
as in males. The confirmation of MTWA potential 
role in SCD risk stratification in this population 
requires further investigation.
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